Sudip Bandhopadhyay, Market Expert told CNBC-TV18, "We are absolutely focused on the segments and the niches. In pharma, we like Aurobindo Pharma. I think it is a good story. We should not paint it with the same brush. They have a huge runway in US. They are probably one of the most compliant companies. Their compliances are way ahead of the others. The number of fillings they have in US is way ahead of others. They have other global market businesses as well."
"At current level we are a buyer in Aurobindo Pharma. We also like Glenmark Pharma and Natco Pharma but if I have to buy one I will go and buy Aurobindo Pharma," he said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!